Published in final edited form as:

J Am Chem Soc. 2015 April 22; 137(15): 4968–4971. doi:10.1021/jacs.5b02631.

A Global and Local Desymmetrization Approach to the Synthesis of Steroidal Alkaloids: Stereocontrolled Total Synthesis of Paspaline

Robert J. Sharpe and Jeffrey S. Johnson*

Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-3290, United States

Abstract

A stereocontrolled total synthesis of the indole diterpenoid natural product paspaline is described. Key steps include a highly diastereoselective enzymatic desymmetrization, substrate-directed epoxidation, Ireland-Claisen rearrangement, and diastereotopic group selective C–H acetoxylation to assemble the target with excellent stereofidelity. The route and results described herein outline complementary conceptual disconnections in the arena of steroid natural product synthesis.

The terpene alkaloids represent a novel subset of natural products due to their unique biological profiles and their departure from the archetypal steroidal motif. The veratrums, for example, have been implicated in prostate, pancreatic, and breast cancers and, as a result, have been investigated as therapeutics.¹ Among these, jervine and cyclopamine have demonstrated marked inhibition of the hedgehog signaling pathway *in vitro* and are currently under study in clinical trials. The structurally distinct indole diterpenoids were first discovered from *Claviceps paspali* in the 1960s with the isolation of paspaline (**1**, Scheme 1);² related compounds including paspalinine,³ paspalicine,² paxilline,⁴ JBIR-03,⁵ and others have since been reported.⁶ Derivatives of paspalinine have shown potent activity as potassium channel antagonists and may be useful in the treatment of glaucoma.⁷ JBIR-03 exhibits anti-MRSA activity and antifungal activity against apple Valsa canker-causing fungus, *Valsa ceratosperma*.⁵

As part of our ongoing efforts in applying stereoselective desymmetrization methods in the synthesis of chiral small molecules,^{8,9} we identified paspaline and its related structures as exemplary targets for investigation. Paspaline's core structure presents a number of synthetic challenges, most notably its three all-carbon quaternary centers (C4a, C12b, C12c). Additionally, the 2,6-*cis*-tetrahydropyranyl F-ring is a unique departure from the classical

© XXXX American Chemical Society

*Corresponding Author: jsj@unc.edu.

Notes

The authors declare no competing financial interest.

ASSOCIATED CONTENTNIHMS681815-supplement.pdf

Supporting Information

Experimental procedures, characterization, and spectral data for all compounds, and crystallographic data (CIF). This material is available free of charge via the Internet at <http://pubs.acs.org>.

steroid structure and requires careful synthetic planning for stereoselective assembly. These synthetic problems have been addressed through varied approaches since paspaline's discovery, significantly via the work of Smith and co-workers.¹⁰ A number of total and partial synthetic studies of paspaline and related molecules have since been disclosed.¹¹ In developing our synthesis plan for paspaline, we noted that the majority of these approaches rely on the use of the Wieland-Miescher ketone as the key intermediate for establishing the C4a stereocenter. While this compound represents a classical "single stereocenter" desymmetrization,¹² we envisaged that a functionalized diketone such as **2** might set the stage for a more complex desymmetrization, simultaneously establishing both the C4a and C14a stereocenters via a biocatalytic diketone monoreduction (**3**) and introducing the functionality required for pyran assembly. In anticipation of the challenges associated with the late-stage creation of the C12b quaternary center,^{10a} we hypothesized that a diastereotopic-group selective C–H activation on dimethyl ketone **4** or its derivatives would establish this critical stereocenter (**5**). This global and local desymmetrization approach would allow maximum control of stereochemical environments en route to **1**.

Our synthesis commenced with establishing the key C4a–C14a stereochemical relationship via reductive desymmetrization of diketone **6** (Scheme 2).¹³ In a racemic sense, the reaction of this compound with NaBH₄ resulted in highly stereoselective monoreduction (20:1 dr), giving the opposite diastereomer to that required. Fortunately, biocatalytic monoreduction of **6** promoted by *Saccharomyces cerevisiae* completely overrode the inherent substrate bias, providing the desired (4a*R*,14a*S*)-relationship in **7** (paspaline numbering) with excellent diastereo- and enantioselectivity.^{14,15} The remaining ketone was then converted to its tosyl hydrazone **8** in 97% yield. The reaction of trisubstituted alkene **8** with *m*-CPBA followed by PPTS led to a stereoselective epoxidation/intramolecular etherification sequence, providing the *cis*-pyran **9** directly in 77% yield and >20:1 dr (15 g scale), and thence the silyl ether **10** upon treatment with TBSOTf. The hydrazone was compulsory for the success of the sequence; when the same epoxidation was carried out on the hydroxy ketone **7**, we isolated only the uncyclized oxirane with poor diastereoselectivity (<2:1). At this juncture, we speculate that the hydrazone in **8** plays a critical role in imposing a favorable reactive conformation on the cyclohexanol, placing the C14a hydroxyl in close proximity to the alkene during oxidation and subsequent ring closure. This reaction represents a rare case of a substrate-directed epoxidation in which the directing group is five carbons from the reaction center.¹⁶

Our next challenge was construction of the sterically congested D-ring in **1** (Scheme 3). We presumed that hydrazone **10** would provide a great deal of flexibility in investigating multiple approaches to D-ring assembly.¹⁷ In the iteration that ultimately proved successful, α -methylation of the dianion derived from **10** followed by in situ deprotonation, Shapiro reaction, and trapping with (HCHO)_n delivered the desired primary allylic alcohol **11** in 64% yield, which upon esterification, gave the isobutyrate **12**. To assemble the C12c angular methyl stereocenter, we surmised that the stereo-chemical outcome of an Ireland-Claisen reaction of ester **12** would be strongly influenced by the axial C4a methyl group; α -approach of the intermediate silyl ketene acetal would provide the requisite 1,3-*syn*-diaxial group relationship.¹⁸ Indeed, enolization of **12** followed by silylation, heating, and hydrolysis gave

the rearrangement product **13** in 80% yield and 6:1 dr. This reaction was the only step in the synthesis that proceeded with less than complete stereocontrol. Esterification and nucleophilic methylation provided the ketone **14** in 84% yield over two steps. Hydroboration/oxidation of **14** proceeded with virtually complete selectivity at C4b to afford diol **15** in 74% yield, and subsequent global oxidation and cyclocondensation concluded D-ring assembly (**16**). Hydrogenation of **16** and condensation of the ketone with *O*-benzyl hydroxylamine proceeded smoothly, giving oxime **17** in 82% yield.

Focus then turned to local desymmetrization to create the C12b all-carbon quaternary stereogenic center (Scheme 4). Cognizant of the fact that the lowest-energy conformation of **17** places the C–N π -bond in plane with the equatorial methyl group, we implemented a directed C–H activation reaction inspired by the report of Sanford and co-workers.^{19,20} In the event, the direct application of Sanford's conditions to oxime **17** provided the desired monoacetate **18** in 79% yield as a single diastereomer (1.6 g scale). This transformation completed assembly of the final quaternary center, which upon global deprotection and oxidation, gave ketoaldehyde **19** poised for synthesis completion.

From tricycle **19**, there remained the challenges of establishing the C6a methine stereocenter and C-ring construction (Scheme 5). The needed carbon atoms were incorporated by bis-vinylation of **19** to give diol **20**,²¹ which, upon ring-closing metathesis, provided allylic alcohol **21** in 71% yield. Acid-catalyzed elimination cleanly delivered the unconjugated enone **22**, which participated in a highly stereoselective catalytic hydrogenation (Pd/C), providing exclusively the epimeric C6a methine stereocenter. This selectivity was not altogether unexpected; catalytic hydrogenation of related steroidal systems have been documented to proceed from the convex face of the bicycle.²² To circumvent this issue, we envisaged reduction of the ketone in **22** might also proceed with analogous convex-face selectivity to give the corresponding alcohol, which would serve as a substrate for directed alkene reduction.²³ Indeed, reduction of **22** upon treatment with LiAlH₄ gave exclusively the (*S*)-hydroxyl **23** in 60% yield over two steps. The stereochemistry of this reaction is of note in that reduction of analogous compounds not bearing the C12a angular methyl group in **1** have proceeded with selectivity orthogonal to that observed in **23**,^{22,24} giving evidence to the impact of this methyl group in facial preference of the ketone in **22**. Catalytic hydrogenation of **23** using Crabtree's catalyst and subsequent oxidation gave ketone **24** in 86% yield over two steps with complete concave surface selectivity. To complete our synthesis, the Gassman indolization of **24** previously employed by Smith proved effective in affording paspaline (**1**) in 46% yield over four steps.^{10a,25} In addition to matching the reported analytical data,^{2a,10d} an X-ray diffraction study of synthetic paspaline provided secondary confirmation of the final structure^{3c} and the sense of enantioinduction imposed in the biocatalytic desymmetrization.²⁶

In summary, a global and local symmetry-breaking approach to the total synthesis of the indole diterpenoid paspaline is reported. Central to our strategy was the implementation of a biocatalytic monoreduction and directed epoxidation to create the E-F bicycle, and a diastereotopic group selective C–H acetoxylation to assemble the C12b quaternary center.

The synthesis collectively demonstrates the viability of these methods in the arena of steroid total synthesis.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The project described was supported by Award No. R01 GM084927 from the National Institute of General Medical Sciences. R.J.S. acknowledges an NSF Graduate Research Fellowship and ACS Division of Organic Chemistry graduate fellowship. X-ray crystallography was performed by Dr. Peter White (UNC).

References

1. Heretsch P, Tzagkaroulaki L, Giannis A. *Angew Chem, Int Ed.* 2010; 49:3418.
2. (a) Fehr T, Acklin W. *Helv Chem Acta.* 1966; 49:1907.(b) Gysi, RP. PhD Dissertation No 4990. Eidgenossische Technische Hochschule; Zürich, Switzerland: 1973. (c) Leutwiler, A. Dissertation No 5163. Eidgenossische Technische Hochschule; Zürich, Switzerland: 1973. (d) Springer JP, Clardy J. *Tetrahedron Lett.* 1980; 21:231. and references therein.
3. (a) Cole RJ, Dorner JW, Lansden JA, Cox RH, Pape C, Cunfer B, Nicholson SS, Bedell DM. *J Agric Food Chem.* 1977; 25:1197. [PubMed: 893851] (b) Cole RJ, Dorner JW, Springer JP, Cox RH. *Agric Food Chem.* 1981; 29:293.(c) Gallagher RT, Finer J, Clardy J, Leutwiler A, Weibel F, Acklin W, Arigoni D. *Tetrahedron Lett.* 1980; 21:235.
4. (a) Cole RJ, Kirksey JW, Wells JM. *Can J Microbiol.* 1974; 20:1159. [PubMed: 4425383] (b) Springer JP, Clardy J, Wells JM, Cole RJ, Kirksey JW. *Tetrahedron Lett.* 1975; 16:2531.
5. Ogata M, Ueda J-y, Hoshi M, Hashimoto J, Nakashima T, Anzai K, Takagi M, Shin-ya K. *J Antibiot.* 2007; 60:645. [PubMed: 17965481]
6. (a) Wilson BJ, Wilson CH. *Science (Washington, DC).* 1964; 144:177.(b) Gallagher RT, Clardy J, Wilson BJ. *Tetrahedron Lett.* 1980; 21:239.(c) De Jesus AE, Steyn PS, Van Heerden FR, Vleggaar R, Wessels PL, Hull WE. *J Chem Soc, Chem Commun.* 1981:289.(d) Wilson BJ, Wilson CH, Hayes AW. *Nature (London, UK).* 1968; 220:77. [PubMed: 4386440]
7. (a) Brnardic, E.; Doherty, JB.; Dorsey, J.; Ellwood, C.; Fillmore, M.; Malaska, M.; Nelson, K.; Soukri, M. Preparation of Indole Diterpene Alkaloids as Maxi-K Channel Blockers for the Treatment of Glaucoma. WIPO. 2009/048559. 2009. (b) Garcia, ML.; Goetz, MA.; Kaczorowski, GJ.; McManus, OB.; Monaghan, RL.; Strohl, WR.; Tkacz, JS. Novel Maxi-K Channel Blockers, Methods of Use and Process for Making the Same. US Patent. 0239863. 2005.
8. (a) Malinowski JT, Sharpe RJ, Johnson JS. *Science.* 2013; 340:180. [PubMed: 23580525] (b) Sharpe RJ, Malinowski JT, Johnson JS. *J Am Chem Soc.* 2013; 135:17990. [PubMed: 24245656] (c) Corbett MT, Johnson JS. *Chem Sci.* 2013; 4:2828. [PubMed: 24683449]
9. For reviews and selected recent examples of the use of stereoselective desymmetrization in synthesis, see Magnuson SR. *Tetrahedron.* 1995; 51:2167. Willis MCJ. *Chem Soc, Perkin Trans.* 1999; 1:1765. Inoue M, Sato T, Hirama M. *J Am Chem Soc.* 2003; 125:10772. [PubMed: 12952441] Karatholuvhu MS, Sinclair A, Newton AF, Alcaraz ML, Stockman RA, Fuchs PL. *J Am Chem Soc.* 2006; 128:12656. [PubMed: 17002353] Qi J, Porco JA Jr. *J Am Chem Soc.* 2007; 129:12682. [PubMed: 17902679] Nicolaou KC, Li A, Edmonds DJ, Tria GS, Ellery SP. *J Am Chem Soc.* 2009; 131:16905. [PubMed: 19874023] Nagatomo M, Koshimizu M, Masuda K, Tabuchi T, Urabe D, Inoue M. *J Am Chem Soc.* 2014; 136:5916. [PubMed: 24708178] Yang M, Li J, Li A. *Nat Commun.* 2015; 6:6445. [PubMed: 25759087]
10. (a) Smith AB III, Mewshaw R. *J Am Chem Soc.* 1985; 107:1769.(b) Smith AB III, Leenay TL. *Tetrahedron Lett.* 1988; 29:2787.(c) Smith AB III, Leenay TL. *Tetrahedron Lett.* 1988; 29:2791. (d) Mewshaw RE, Taylor MD, Smith AB III. *J Org Chem.* 1989; 54:3449.(e) Smith AB III, Leenay TL. *J Am Chem Soc.* 1989; 111:5761.(f) Smith AB III, Sunazuka T, Leenay TL, Kingery-Wood J. *J Am Chem Soc.* 1990; 112:8197.(g) Smith AB III, Kingery-Wood J, Leenay TL, Nolen

- EG, Sunazuka T. *J Am Chem Soc.* 1992; 114:1438.(h) Smith AB III, Ohta M, Clark WM, Leahy JW. *Tetrahedron Lett.* 1993; 34:3033.(i) Smith AB III, Nolen EG, Shirai R, Blase FR, Ohta M, Chida N, Hartz RA, Fitch DM, Clark WM, Sprengeler PA. *J Org Chem.* 1995; 60:7837.(j) Smith AB III, Hartz RA, Spoor PG, Rainier JD. *Israel J Chem.* 1997; 37:69.(k) Smith AB III, Kanoh N, Minakawa N, Rainier JD, Blase FR, Hartz RA. *Org Lett.* 1999; 1:1263. [PubMed: 10825977] (l) Smith AB III, Kanoh N, Ishiyama H, Hartz RA. *J Am Chem Soc.* 2000; 122:11254.(m) Smith AB III, Davulcu AH, Kürti L. *Org Lett.* 2006; 8:1665. [PubMed: 16597136] (n) Smith AB III, Kürti L, Davulcu AH, Cho YS, Ishiyama H, Ohmoto K. *J Org Chem.* 2007; 72:4611. [PubMed: 17511508]
11. (a) Guile SD, Saxton JE, Thornton-Pett MJ. *Chem Soc, Perkin Trans.* 1992; 1:1763.(b) Clark JS, Myatt J, Roberts L, Walshe N. *Synlett.* 2005:697.(c) Churrua F, Fousteris M, Ishikawa Y, Rekowski MW, Hounsou C, Surrey T, Giannis A. *Org Lett.* 2010; 12:2096. [PubMed: 20387880] (d) Enomoto M, Kuwahara S. *J Org Chem.* 2010; 75:6286. [PubMed: 20718438] (e) Bradshaw B, Etxebarria-Jardi G, Bonjoch J. *J Am Chem Soc.* 2010; 132:5966. [PubMed: 20384301] (f) Oikawa M, Hashimoto R, Sasaki M. *Eur J Org Chem.* 2011:538.(g) Isaka T, Hasegawa M, Toshima H. *Biosci Biotechnol Biochem.* 2011; 75:2213. [PubMed: 22056442] (h) Adachi M, Higuchi K, Thasasa N, Yamada H, Nishikawa T. *Org Lett.* 2012; 14:114. [PubMed: 22126279] (i) Okano K, Yoshii Y, Tokuyama H. *Heterocycles.* 2012; 84:1325.(j) Enomoto M, Morita A, Kuwahara S. *Angew Chem, Int Ed.* 2012; 51:12833.(k) Bian M, Wang Z, Xiong X, Sun Y, Matera C, Nicolaou KC, Li A. *J Am Chem Soc.* 2012; 134:8078. [PubMed: 22537293] (l) Goetz AE, Silberstein AL, Corsello MA, Garg NK. *J Am Chem Soc.* 2014; 136:3036. [PubMed: 24524351]
12. (a) Eder U, Sauer G, Wiechert R. *Angew Chem.* 1971; 83:492.(b) Hajos ZG, Parrish DR. *J Org Chem.* 1973; 38:3239. [PubMed: 4733451] (c) Hajos ZG, Parrish DR. *J Org Chem.* 1974; 39:1615. (d) Micheli RA, Hajos ZG, Cohen N, Parrish DR, Portland LA, Sciamanna W, Scott MA, Wehrli PA. *J Org Chem.* 1975; 40:675. [PubMed: 1133631]
13. Ketone **6** was synthesized via a modification of Enders' procedure. Demir AS, Enders D. *J Prakt Chem.* 1997; 339:553.
14. (a) Watanabe H, Iwamoto M, Nakada M. *J Org Chem.* 2005; 70:4652. [PubMed: 15932301] (b) Katoh T, Mizumoto S, Fudesaka M, Nakashima Y, Kajimoto T, Node M. *Synlett.* 2006:2176.(c) Katoh T, Mizumoto S, Fudesaka M, Takeo M, Kajimoto T, Node M. *Tetrahedron: Asymmetry.* 2006; 17:1655.
15. For examples of this type of transformation in total synthesis, see: Yeung Y, Chein RJ, Corey EJ. *J Am Chem Soc.* 2007; 129:10346. [PubMed: 17672468] Liu LL, Chiu P. *Chem Commun.* 2011; 47:3416.Breitler S, Carreira EM. *Angew Chem, Int Ed.* 2013; 52:11168.
16. Other examples of remote direction in alkene functionalization: Zhang W, Yamamoto H. *J Am Chem Soc.* 2007; 129:286. [PubMed: 17212403] Wan KK, Iwasaki K, Umotoy JC, Wolan DW, Shenvi RA. *Angew Chem, Int Ed.* 2015; 54:2410.
17. (a) Shapiro RH, Heath MJ. *J Am Chem Soc.* 1967; 89:5734.(b) Shapiro RH. *Org React (NY, Engl Transl).* 1975; 23:405.
18. (a) Ireland RE, Mueller RH. *J Am Chem Soc.* 1972; 94:5897.(b) Ireland RE, Mueller RH, Willard AK. *J Am Chem Soc.* 1976; 98:2868.
19. (a) Desai LV, Hull KL, Sanford MS. *J Am Chem Soc.* 2004; 126:9542. [PubMed: 15291549] (b) Neufeldt SR, Sanford MS. *Org Lett.* 2010; 12:532. [PubMed: 20041702]
20. (a) Siler DA, Mighion JD, Sorenson EJ. *Angew Chem, Int Ed.* 2014; 53:5332.(b) Meng Z, Yu H, Li L, Tao W, Chen H, Wan M, Yang P, Edmonds D, Zhong J, Li Ang. *Nat Commun.* 2015; 6:6096. [PubMed: 25648883]
21. Krasovskiy A, Kopp F, Knochel P. *Angew Chem, Int Ed.* 2006; 45:497.
22. Abad A, Agullo C, Arno M, Domingo LR, Zaragoza RJ. *J Org Chem.* 1990; 55:2369. and references therein.
23. (a) Evans DA, Morrissey M. *J Am Chem Soc.* 1984; 106:3866.(b) Evans DA, Morrissey M. *Tetrahedron Lett.* 1984; 25:4637.
24. (a) St André AF, MacPhillamy HB, Nelson JA, Shabica AC, Scholz CR. *J Am Chem Soc.* 1952; 74:5506.(b) Gabbard RB, Segaloff A. *Steroids.* 1983; 41:791. [PubMed: 6665822] (c) Haddad M, Blazejewski JC, Wakselman C, Dorai V, Duc I. *Eur J Med Chem.* 1994; 29:627.(d) Khripach VA, Zhabinskii VN, Fando GP, Kuchto AI, Lyakhov AS, Govorova AA, Groen MB, van der Louw J, De Groot A. *Steroids.* 2004; 69:495. [PubMed: 15246779]

25. Gassman PG, van Bergen TJ, Gilbert DP, Cue BW Jr. *J Am Chem Soc.* 1974; 96:5495.
26. CCDC 1052642 contains the supplementary crystallographic data for this paper. This data can be obtained free of charge from the Cambridge Crystallographic Centre via www.ccdc.cam.ac.uk/data_request/cif

■ C4a-C14a stereocenters

■ C12b quaternary center

Scheme 1.
Synthesis Plan for Paspaline

Scheme 2. Stereocontrolled Synthesis of E- and F-Rings^a

^aConditions: (a) YSC-2, H₂O:DMSO (10:1), 30 °C; (b) TsHNNH₂, C₇H₈, 70 °C; (c) *m*-CPBA, CH₂Cl₂, 0 °C, then PPTS (10 mol %), rt; (d) TBSOTf, 2,6-lutidine, CH₂Cl₂, -50 °C.

Scheme 3. D-Ring Construction and 1,3-Bis Angular Methyl Group Installation^a

^aConditions: (a) *n*BuLi, THF, -50 °C, then MeI; *n*BuLi, -50 °C to rt, then (HCHO)_n; (b) isobutyric acid, DCC, DMAP (10 mol %), CH₂Cl₂, rt; (c) LDA, THF, -78 °C, then TMSCl, -78 to 75 °C; (d) TMSCHN₂, MeOH:C₇H₈ (2:1), rt; (e) MeLi, Et₂O, 0 °C to rt; (f) BH₃·THF, THF, 50 °C, then H₂O₂, NaOH, 0 °C to rt; (g) (COCl)₂, DMSO, CH₂Cl₂, -78 °C, then DIPEA, -78 to 0 °C; (h) KOH, THF:MeOH (1:1), 0 °C to rt; (i) H₂ (1 atm), Pd/C (1.5 mass equiv), EtOAc, rt; (j) NH₂OBn·HCl, NaOAc, MeOH:H₂O (5:1), 85 °C.

Scheme 4. Local Desymmetrizing C–H Activation to Establish C12b Angular Methyl Stereochemistry^a

^aConditions: (a) Pd(OAc)₂ (15 mol %), PhI(OAc)₂, AcOH:Ac₂O (1:1), 100 °C; (b) HCl, H₂O:MeOH:THF:acetone (10:10:10:1), 85 °C; (c) DMP, CH₂Cl₂, rt.

Scheme 5. C-Ring Construction and Synthesis Completion^a

^aConditions: (a) vinylmagnesium bromide, $\text{CeCl}_3 \cdot 2\text{LiCl}$, THF, -78°C ; (b) Grubbs second gen. catalyst (20 mol %), CH_2Cl_2 , rt; (c) TFA, CH_2Cl_2 , 0°C to rt; (d) LiAlH_4 , THF, 0°C ; (e) H_2 (1 atm), $[\text{C}_8\text{H}_{12}]\text{IrP}(\text{C}_6\text{H}_{11})_3\text{C}_5\text{H}_5\text{N}]\text{PF}_6$ (15 mol %), CH_2Cl_2 , rt; (f) DMP, CH_2Cl_2 , rt. (g) LDA, THF, 0°C , then HMPA, Me_2S_2 ; (h) *N*-chloroaniline, CH_2Cl_2 , -78°C , then NEt_3 ; (i) Raney Ni, EtOH, rt; (j) TsOH (66 mol %), CH_2Cl_2 , 50°C .